Polaryx Therapeutics, Inc. (PLYX) Balance Sheet
PLYX balance sheet, 2025
December 31, 2025 · U.S. dollars$5.4M assets = $855,000 liabilities + $4.6M equity
Both columns are drawn to the same scale: what PLYX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PLYX financial health
Descriptive bands, not a rating. Fiscal 2025.
PLYX balance sheet trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $2.3M2023 | $5.4M2025 | +53.0%/yr | |
| Total liabilities | $1.0M2023 | $855,0002025 | −9.2%/yr | |
| Shareholders’ equity | $1.3M2023 | $4.6M2025 | +89.1%/yr | |
| Cash & short-term investments | $2,0002023 | $5.1M2025 | +4,971.0%/yr | |
| Working capital | $1.3M2023 | $4.6M2025 | +$3.3M | |
| Book value per share | $0.012023 | $0.102025 | +278.1%/yr | |
| Current ratio | 2.232023 | 8.552025 | +6.32 | |
| Shares outstanding | 189.4M2023 | 47.3M2025 | −50.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PLYX assets
PLYX liabilities and equity
PLYX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PLYX balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $5.1M | $4.6M | $2,000 |
| Cash & equivalents | $5.1M | $4.6M | $2,000 |
| Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other current assets | $27,000 | $380,000 | $2.3M |
| Total current assets | $5.2M | $5.0M | $2.3M |
| Property, plant & equipment (net) | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 |
| Other non-current assets | $250,000 | $0 | $0 |
| Total assets | $5.4M | $5.0M | $2.3M |
| Liabilities | |||
| Accounts payable | $470,000 | $72,000 | $473,000 |
| Short-term debt | — | — | $128,000 |
| Total current liabilities | $605,000 | $289,000 | $1.0M |
| Long-term debt | $0 | $0 | $0 |
| Other long-term liabilities | $250,000 | $0 | $0 |
| Total liabilities | $855,000 | $289,000 | $1.0M |
| Shareholders' equity | |||
| Common stock & paid-in capital | $5,000 | $16,000 | $4,000 |
| Retained earnings (deficit) | −$99.6M | −$90.7M | −$60.3M |
| Total shareholders' equity | $4.6M | $4.7M | $1.3M |
| Key figures | |||
| Total debt | — | — | $128,000 |
| Net cash (debt) | — | — | −$126,000 |
| Working capital | $4.6M | $4.7M | $1.3M |
| Tangible book value | $4.6M | $4.7M | $1.3M |
| Book value per share | $0.10 | $0.02 | $0.01 |
| Shares outstanding | 47.3M | 189.4M | 189.4M |
| Current ratio | 8.55 | 17.30 | 2.23 |
| Quick ratio | 8.50 | 15.99 | 0.00 |
| Debt / equity | — | — | 0.10 |
| Equity / assets | 84.2% | 94.2% | 55.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $11.5M | $3.1M | $5.1M | $5.7M | $3.3M | $4.2M | $4.6M |
| Cash & equivalents | $11.5M | $3.1M | $5.1M | $5.7M | $3.3M | $4.2M | $4.6M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $270,000 | $422,000 | $27,000 | $238,000 | $239,000 | $276,000 | $380,000 |
| Total current assets | $11.8M | $3.5M | $5.2M | $6.0M | $3.5M | $4.4M | $5.0M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $250,000 | $0 | $0 | $0 | $0 |
| Total assets | $11.8M | $3.5M | $5.4M | $6.0M | $3.5M | $4.4M | $5.0M |
| Liabilities | |||||||
| Accounts payable | $683,000 | $850,000 | $470,000 | $496,000 | $158,000 | $55,000 | $72,000 |
| Total current liabilities | $873,000 | $1.0M | $605,000 | $682,000 | $296,000 | $185,000 | $289,000 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $250,000 | $0 | $0 | $0 | $0 |
| Total liabilities | $873,000 | $1.0M | $855,000 | $682,000 | $296,000 | $185,000 | $289,000 |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $5,000 | $5,000 | $5,000 | $19,000 | $18,000 | $18,000 | $16,000 |
| Retained earnings (deficit) | −$103.6M | −$102.2M | −$99.6M | −$98.1M | −$96.7M | −$95.7M | −$90.7M |
| Total shareholders' equity | $10.9M | $2.5M | $4.6M | $5.3M | $3.2M | $4.3M | $4.7M |
| Key figures | |||||||
| Working capital | $10.9M | $2.5M | $4.6M | $5.3M | $3.2M | $4.3M | $4.7M |
| Tangible book value | $10.9M | $2.5M | $4.6M | $5.3M | $3.2M | $4.3M | $4.7M |
| Book value per share | $0.23 | $0.05 | $0.10 | $0.03 | $0.02 | $0.02 | $0.02 |
| Shares outstanding | 48.3M | 47.2M | 47.3M | 189.4M | 189.4M | 189.4M | 189.4M |
| Current ratio | 13.53 | 3.45 | 8.55 | 8.77 | 11.97 | 23.99 | 17.30 |
| Quick ratio | 13.22 | 3.04 | 8.50 | 8.42 | 11.16 | 22.50 | 15.99 |
| Equity / assets | 92.6% | 71.0% | 84.2% | 88.6% | 91.6% | 95.8% | 94.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
PLYX financial position
At the end of fiscal 2025 (December 31, 2025), Polaryx Therapeutics had total assets of $5.4 million (up 8.4% from a year earlier), total liabilities of $0.9 million and shareholders' equity of $4.6 million. Its current ratio was 8.55. In the latest quarter (ended June 30, 2026) total assets were $11.8 million and equity $10.9 million.
Related: PLYX income statement, PLYX cash flow statement, PLYX key metrics. See the PLYX stock overview for the latest quote and news.
PLYX balance sheet FAQ
What are Polaryx Therapeutics's total assets?
Polaryx Therapeutics reported total assets of $5.4 million at the end of fiscal 2025 (December 31, 2025), compared with $5.0 million a year earlier.
How much cash does Polaryx Therapeutics have?
Polaryx Therapeutics held $5.1 million in cash and short-term investments at the end of fiscal 2025.
What is Polaryx Therapeutics's book value?
Polaryx Therapeutics's shareholders' equity (book value) was $4.6 million at the end of fiscal 2025, or $0.10 per share.
What is Polaryx Therapeutics's current ratio?
Polaryx Therapeutics had current assets of $5.2 million and current liabilities of $0.6 million, a current ratio of 8.55 (it can cover its short-term obligations).